Nicox
en
fr
Toggle Menu
About Us
Visible Science
Disease Focus Areas
Leadership Team
Board of Directors
Glaucoma Advisory Board
Partnerships
Pipeline, Markets and Science
Nicox Products and Product Candidates
Ophthalmology Market
Our portfolio at a glance
Nitric Oxide Donation
Publications
Investors
Stock Information
Financial and Regulatory Information
Shareholder Meetings
Corporate Presentation
Webcasts
Corporate Governance
Investor Contacts
News and Events
Press Releases
Events and Conferences
Videos
Contact Us
Contact Details
Main subsidiaries
Job opportunities
Nicox’s Partner Secures Additional Approval of VYZULTA® (latanoprostene bunod ophthalmic solution), 0.024% in Taiwan
March 9, 2020
← Back to blog page
Cookies
By continuing to use this website, you agree to our
Cookie Policy
.
Accept
